MA49374A - Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine - Google Patents

Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine

Info

Publication number
MA49374A
MA49374A MA049374A MA49374A MA49374A MA 49374 A MA49374 A MA 49374A MA 049374 A MA049374 A MA 049374A MA 49374 A MA49374 A MA 49374A MA 49374 A MA49374 A MA 49374A
Authority
MA
Morocco
Prior art keywords
vanine
inhibitors
compounds used
heteroaromatic compounds
heteroaromatic
Prior art date
Application number
MA049374A
Other languages
English (en)
Inventor
Todd Bosanac
Michael J Burke
Brian Nicholas Cook
Darren Todd Disalvo
Jr Thomas Martin Kirrane
Yue Shen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA49374A publication Critical patent/MA49374A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA049374A 2017-06-12 2018-06-08 Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine MA49374A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762518106P 2017-06-12 2017-06-12

Publications (1)

Publication Number Publication Date
MA49374A true MA49374A (fr) 2021-04-21

Family

ID=62631060

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049374A MA49374A (fr) 2017-06-12 2018-06-08 Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine

Country Status (23)

Country Link
US (2) US10364255B2 (fr)
EP (1) EP3638680B1 (fr)
JP (1) JP6880243B2 (fr)
KR (1) KR102607934B1 (fr)
CN (1) CN110770242B (fr)
AR (1) AR112086A1 (fr)
AU (1) AU2018285131B2 (fr)
CA (1) CA3066946A1 (fr)
CL (1) CL2019003515A1 (fr)
CO (1) CO2019013823A2 (fr)
DK (1) DK3638680T3 (fr)
EA (1) EA039223B1 (fr)
ES (1) ES2927021T3 (fr)
HU (1) HUE060597T2 (fr)
IL (1) IL271104B (fr)
MA (1) MA49374A (fr)
MX (1) MX394645B (fr)
PE (1) PE20200340A1 (fr)
PH (1) PH12019502693A1 (fr)
PL (1) PL3638680T3 (fr)
TW (1) TWI855993B (fr)
UA (1) UA124948C2 (fr)
WO (1) WO2018228934A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
AU2018285131B2 (en) * 2017-06-12 2021-11-11 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
HUE061186T2 (hu) 2018-08-28 2023-06-28 Boehringer Ingelheim Int Heteroaromás vegyületek mint vanin-inhibitorok
WO2020104494A1 (fr) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques
ES2928919T3 (es) 2018-12-03 2022-11-23 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina
JP7130873B2 (ja) 2018-12-03 2022-09-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング バニン阻害剤としてのヘテロ芳香族化合物
BR112021010823A2 (pt) 2018-12-03 2021-08-24 Boehringer Ingelheim International Gmbh Compostos heteroaromáticos como inibidores de vanina
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
WO2021174024A1 (fr) 2020-02-28 2021-09-02 First Wave Bio, Inc. Méthodes de traitement de la colite auto-immune iatrogène
MX2025011827A (es) 2023-04-10 2025-12-01 UMOV SpA Sistema de rehabilitación y monitoreo.
WO2025261536A1 (fr) * 2024-06-21 2025-12-26 长春金赛药业有限责任公司 Intermédiaire clé de ligand d'intégrine et son procédé de préparation
CN118892548A (zh) * 2024-08-12 2024-11-05 中国人民解放军陆军特色医学中心 Vanin-1抑制剂在制备治疗急性肾损伤继发急性肺损伤的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540868A1 (fr) * 2003-10-09 2005-04-21 Abbott Laboratories Derives de pyrrolidinyle- uree utilises comme inhibiteurs de l'angiogenese
WO2016193844A1 (fr) 2015-05-29 2016-12-08 Pfizer Inc. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1
US10906888B2 (en) * 2016-07-14 2021-02-02 Pfizer Inc. Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
AU2018285131B2 (en) * 2017-06-12 2021-11-11 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors

Also Published As

Publication number Publication date
DK3638680T3 (da) 2022-09-05
JP6880243B2 (ja) 2021-06-02
TW201920196A (zh) 2019-06-01
US10364255B2 (en) 2019-07-30
HUE060597T2 (hu) 2023-04-28
AR112086A1 (es) 2019-09-18
PH12019502693A1 (en) 2020-07-13
US20180354968A1 (en) 2018-12-13
CA3066946A1 (fr) 2018-12-20
IL271104B (en) 2022-03-01
KR102607934B1 (ko) 2023-12-01
EP3638680B1 (fr) 2022-08-10
AU2018285131A1 (en) 2019-10-31
EA202090014A1 (ru) 2020-05-12
CN110770242B (zh) 2022-08-19
PL3638680T3 (pl) 2022-12-19
TWI855993B (zh) 2024-09-21
KR20200013718A (ko) 2020-02-07
AU2018285131B2 (en) 2021-11-11
MX394645B (es) 2025-03-21
PE20200340A1 (es) 2020-02-14
UA124948C2 (uk) 2021-12-15
EA039223B1 (ru) 2021-12-20
US20190263828A1 (en) 2019-08-29
CO2019013823A2 (es) 2020-01-17
EP3638680A1 (fr) 2020-04-22
CL2019003515A1 (es) 2020-06-19
CN110770242A (zh) 2020-02-07
WO2018228934A1 (fr) 2018-12-20
JP2020522517A (ja) 2020-07-30
IL271104A (en) 2020-01-30
BR112019021703A2 (pt) 2020-05-12
ES2927021T3 (es) 2022-11-02
MX2019014876A (es) 2020-02-13

Similar Documents

Publication Publication Date Title
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
EP3768661A4 (fr) Composés deutérés utilisés en tant qu'inhibiteurs de rock
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
EP3533787A4 (fr) Composé de pyridone en tant qu'inhibiteur de c-met
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3621624A4 (fr) Composés dinucléotidiques cycliques en tant qu'agonistes sting